Related Experiment Videos

Recombinant antibodies for the selective targeting of tumor neovasculature

Francesca Viti1, Leonardo Giovannoni, Dario Neri

  • 1Swiss Federal Institute of Technology Zurich, Institute of Pharmaceutical Sciences, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.

Current Opinion in Drug Discovery & Development
|April 3, 2002
PubMed

Insights

Recombinant antibodies target new blood vessels in tumors and diseases like cancer. This approach offers new ways to image and treat angiogenesis-related conditions.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for aggressive solid tumors.
  • Identifying angiogenesis markers and producing recombinant antibodies enables targeted delivery of molecules to tumor neovasculature.

Purpose of the Study:

  • To review the potential of recombinant antibody derivatives for targeting angiogenesis.
  • To explore applications in imaging and therapy for angiogenesis-related diseases.

Main Methods:

  • Review of current literature on angiogenesis markers.
  • Analysis of advancements in human recombinant antibody production.
  • Discussion of targeted delivery strategies to tumor neovasculature.

Main Results:

  • Recombinant antibody derivatives show promise for selective delivery of bioactive molecules.
  • Potential applications identified for cancer, blinding ocular disorders, and rheumatoid arthritis.

Conclusions:

  • Recombinant antibody technology offers novel strategies for the imaging and therapy of angiogenesis.
  • Targeted approaches can improve treatment outcomes for angiogenesis-dependent diseases.

Related Concept Videos